Neoadjuvant cisplatin, pemetrexed plus atezolizumab followed by surgical resection, maintenance atezolizumab is safe

Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria, according to research presented today in OA13: Topics in Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer.